Stockreport

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Holdings Inc.  (ENGN) 
PDF Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 resultsFavorable tolerability profile with no drug-related discontinuationsDet [Read more]